Company Overview and News

 
Brokerages remain upbeat on Indiabulls Housing post Q2, see 40-60% upside

1h moneycontrol
JPMorgan, Macquarie, as well as CLSA maintained their ratings on Indiabulls Housing Finance post Q2 results and see 40-60 percent upside from current levels.
535789 IBULHSGFIN IDKQY

 
Indiabulls Housing shares jump 3%

1h thehindubusinessline
Share of Indiabulls Housing Finance jumped as much as 3 per cent to Rs 976.80 as the mortgage lender had on Mondday posted 21.5 per cent rise in September quarter profit of Rs 1,044 crore ($141.28 million).
SOUTHBANK 535789 IBULHSGFIN IDKQY 532218

 
Indiabulls Housing Finance opens 2% higher on strong Q2 results

3h moneycontrol
Shares of Indiabulls Housing Finance (IBHFL) climbed 2 percent in early trade after the company reported strong results for the second quarter.
535789 IBULHSGFIN IDKQY

 
Indiabulls Housing profit rises 16%

15h thehindubusinessline
Indiabulls Housing Finance reported a 16 per cent increase in standalone net profit at ₹933 crore in the second quarter ended September 30, 2018, against ₹804 crore in the year-ago period.
535789 IBULHSGFIN IDKQY

 
Indiabulls Housing Finance Q2 profit jumps 21% to Rs 1,044 cr

17h moneycontrol
Indiabulls Housing Finance (IBHFL) reported a profit of Rs 1,044.1 crore for the second quarter of the current fiscal, up 21.2 percent over the year ago period. The company's profit after tax (PAT) was Rs 861.3 crore during July-September quarter of 2017-18.
535789 IBULHSGFIN IDKQY

 
Indiabulls Housing Finance Limited - Updates

19h nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
535789 IBULHSGFIN IDKQY

 
Indiabulls Housing Finance Limited - Record Date

19h nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
535789 IBULHSGFIN IDKQY

 
Indiabulls Housing Finance Limited - Updates

19h nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
535789 IBULHSGFIN IDKQY

 
Indiabulls Housing Finance Limited - Outcome of Board Meeting

20h nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
535789 IBULHSGFIN IDKQY

 
D-Street Buzz: Nifty IT, pharma outperforms led by KPIT Tech, Dr Reddy#39;s Labs; auto drags

2018-10-15 moneycontrol
The Indian benchmark indices are trading in the red this Monday morning with the Nifty50 down 25 points, trading at 10,446 while the Sensex shed 47 points at 34,685.
IOC BAJAJ-AUTO 500408 500325 524816 RELIANCE TCHQY 532218 532977 532755 CADILAHC 535789 505200 SOUTHBANK 532343 532321 NATCOPHARM PINCON RIGD GAILF EICHERMOT RLNIY ECQRY 538771 TVSMOTOR IDKQY 530965 CDLYY TECHM IBULHSGFIN GAILY TATAELXSI DCMSHRIRAM 523367

 
Share market LIVE updates: Sensex, Nifty likely to open lower; IndusInd Bank Q2 results to watch out for today

2018-10-15 financialexpress
Share market live today: The Sensex and Nifty are expected to open on a lower note on Monday tracking weak cues from the Asian markets. SGX Nifty futures were trading marginally lower at 10,469, down 10 points or 0.10%, at the Singapore Exchange, indicating a lower start of the NSE Nifty. IndusInd Bank and Indiabulls Housing Finance are the two Nifty companies which are expected to declare their quarterly corporate results later today.
535789 IBULHSGFIN SPXCY 532187 SPXCF INDUSINDBK IDKQY S68

 
MF Wrap: Why mutual funds pared stake in NBFCs, HFCs in September?

2018-10-13 moneycontrol
Mutual funds pared stake in most non-banking and housing finance companies or NBFCs in September as defaults in repayment by group companies of Infrastructure Leasing & Financial Services (IL&FS) and subsequent ratings downgrades led to fears of a contagion in the sector.
511218 535789 IBULHSGFIN DHFL RELCAPITAL 511072 SRRQY IDKQY SRTRANSFIN 500111

 
IndusInd Bank, DMart, IB Finance results

2018-10-12 thehindubusinessline
AU Small Finance Bank, Avenue Supermarts and Jay Bharat Maruti will declare their quarterly financial results for the period ended September 2018 on Saturday. Over a dozen firms including Alkali Metals, Delta Corp, Indiabulls Housing Finance, IndusInd Bank, JK Agri, Network18 Media, Monnet Ispat, MT Educare, Pitti Engineering, Reliance Industrial Infra, Trident, TV18 Broadcast, Zee Media Corporation and Zee Learn will announce their numbers on Monday.
ZEELEARN INDUSINDBK IDKQY JAYBARMARU 533287 532800 534312 535789 IBULHSGFIN 533029 532187 MTEDUCARE ALKALI TV18BRDCST 520066

 
Indiabulls Housing Finance Limited - Updates

2018-10-12 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
535789 IBULHSGFIN IDKQY

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...